Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.34 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | MMP9 | P14780 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | FASN | P49327 | 3/20 | 0.32 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | GLI1 | P08151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20293481 | 1.00 | MME (0.34) | MMEMMP2MMP9CA12CA1 | |
| SCHEMBL27903631 | 0.89 | MME (0.33) | MMEMMP2MMP9CA12CA1 | |
| SCHEMBL1503908 | 0.89 | MME (0.33) | MMEMMP2MMP9CA12CA1 | |
| Benzoic Acid SCHEMBL20293503 | 0.87 | FASN (0.38) | FASN | |
| Citric Acid SCHEMBL20293589 | 0.86 | ALDH1A1 (0.36) | MME | |
| Oxalic Acid SCHEMBL4114848 | 0.86 | MME (0.32) | MMEFASNPDE7ADPP4 | |
| Oxalic Acid SCHEMBL14908944 | 0.84 | DPP4 (0.32) | MMEFASNPDE7ADPP4 | |
| SCHEMBL20328944 | 0.83 | MME (0.31) | MME | |
| Sulfuric Acid SCHEMBL17472893 | 0.83 | MME (0.31) | MMEFASN | |
| SCHEMBL20293667 | 0.83 | TSHR (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301322-B2 | Processes for the preparation of edoxaban and intermediates thereof | APOTEX INC. (CA) | 2019-05-28 | — | — | US | disclosed |
| US-20180179226-A1 | Processes for the Preparation of Edoxaban and Intermediates Thereof | THE BANK OF NOVA SCOTIA (CA) | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301322-B2 | Processes for the preparation of edoxaban and intermediates thereof | VKORC1, CYP2C9, VKORC1L1 | MME 2026/4885MMP2 964/4885MMP9 261/4885 |
| US-20180179226-A1 | Processes for the Preparation of Edoxaban and Intermediates Thereof | VKORC1, CYP2C9, VKORC1L1 | MME 2026/4885MMP2 964/4885MMP9 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.